Earnings Summary

Alnylam Pharmaceuticals, Inc.’s revenue jumped 54.82% since last year same period to $494.33Mn in the Q1 2024. On a quarterly growth basis, Alnylam Pharmaceuticals, Inc. has generated 12.42% jump in its revenue since last 3-months.

Alnylam Pharmaceuticals, Inc.’s net profit jumped 62.13% since last year same period to $-65.94Mn in the Q1 2024. On a quarterly growth basis, Alnylam Pharmaceuticals, Inc. has generated 52.18% jump in its net profits since last 3-months.

Alnylam Pharmaceuticals, Inc.’s net profit margin jumped 75.54% since last year same period to -13.34% in the Q1 2024. On a quarterly growth basis, Alnylam Pharmaceuticals, Inc. has generated 57.46% jump in its net profit margins since last 3-months.

Alnylam Pharmaceuticals, Inc.’s earning per share (EPS) estimates for the current quarter stand at -1.09 - a 7.63% jump from last quarter’s estimates.

Alnylam Pharmaceuticals, Inc.’s earning per share (EPS) estimates for the current year stand at -1.09.

Alnylam Pharmaceuticals, Inc.’s earning per share (EPS) jumped 62.86% since last year same period to -0.52 in the Q1 2024. This indicates that the Alnylam Pharmaceuticals, Inc. has generated 62.86% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Alnylam Pharmaceuticals, Inc.’s return on assets (ROA) stands at -0.03.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Alnylam Pharmaceuticals, Inc.’s return on equity (ROE) stands at -15.01.